News of Note—Merck’s Zostavax, GeoVax and more

In this week's news of note, an appeals court upheld a lower court's decision to throw out a Zostavax injury lawsuit. (Pixabay)

Here is some other vaccine news of note for the week.

> A U.S. Circuit Court of Appeals affirmed a lower court's decision to throw out a Zostavax injury lawsuit against Merck due to the statute of limitations. Court opinion (PDF)

> GeoVax nabbed $300,000 from the NIH’s National Institute of Allergy and Infectious Diseases to support a phase 1 study of its Lassa fever vaccine program. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The University of Washington’s Institute for Protein Design won a $11.3 million grant from the Open Philanthropy Project; about half of it will go toward the development of a universal flu vaccine. GeekWire article

> Using education campaigns to change people’s minds about vaccines is less effective than using behavioral nudges, a new study published in Psychological Science in the Public Interest found. Release

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.